



Familial Pancreatic Cancer

Familial pancreatic cancer is usually defined by the presence of 2 or more close relatives with pancreatic cancer. 5-10% of pancreatic cancers are related to a hereditary cancer syndrome including: Peutz-Jeghers, Familial Melanoma, Hereditary Breast/Ovarian Cancer and Lynch syndrome.

The Familial Pancreatic Cancer Program (FPCP) is part of BC Cancer's Hereditary Cancer Program. The goals of this clinical research program are to further our understanding of the causes of pancreatic cancer, evaluate the contribution of genetic factors, and develop a pancreatic cancer screening research protocol.

Hereditary Cancer Program referral should be considered for a person with:

- personal history of:
 - pancreatic ductal adenocarcinoma (see also urgent storage of a blood sample)
 - intraductal papillary mucinous neoplasm or pancreatic intraepithelial neoplasia
 - pancreatic neuroendocrine tumour
- family history of:
 - 1 or more close relatives with pancreatic ductal adenocarcinoma

People with a confirmed hereditary cancer syndrome can also connect with the FPCP if their family history includes a close relative with pancreatic cancer.

Lifetime Pancreatic Cancer Risks

general population (men and women):	1.5%
1 close relative with pancreatic cancer:	3-5% (increased by 2-3 times)
2 close relatives with pancreatic cancer:	8-12%
3 close relatives with pancreatic cancer:	16-30%

Pancreatic Cancer Risk Management Recommendations

Avoiding smoking, getting regular exercise, maintaining a healthy weight and diet, and limiting alcohol intake are likely to be beneficial for people with increased pancreatic cancer risk.

There is a need for further evidence of benefit from pancreatic cancer screening with currently available methods. In the meantime, people with family history of pancreatic cancer may consider referral for

baseline assessment with a GI specialist at a centre with expertise to discuss the benefits and limitations of current surveillance methods.

The BC Cancer Familial Pancreatic Cancer Program is part of the PRECEDE Consortium (precedestudy.org), which will evaluate the impact and outcomes of pancreatic cancer screening.

Additional Information

Video series: <https://www.youtube.com/playlist?list=PL5xuSF2N71CvwEhBXLUcQiToNrsYt5u2J>

FPCP: <http://pancreascentrebc.ca/research#panel-5>

Reviewed June 2022